Background: Emerging evidence identified sex as a variable regulating immune system functions and modulating response to immunotherapy in cancer patients. Objective: This retrospective study analysed sex-related differences in immunotherapy outcomes in a real-world population of non-small cell lung cancer (NSCLC) patients treated with immune check point inhibitors (ICIs). Methods: We retrospectively investigated clinical data of 99 patients with advanced NSCLC and treated with single-agent nivolumab and pembrolizumab at Medical Oncology Unit, Careggi Universi ty Hospital, Florence (Italy), between April 2014 to August 2019. Main clinical characteristics and clinical outcomes were analysed. Results: Our study showed that the efficacy of ICI treatment differed according to gender. A trend for better median progression-free survival (mPFS) was reported in males (mPFS 5.0 months, 95% Con fidence Interval [CI] 4.0-11.0) than females (mPFS 4.5 months, 95% CI 2.0-9.0) (p=0.133), while no significant difference for overall survival (OS) between the two sex groups was observed (p=0.622). In the nivolumab cohort, we showed a statistically significant difference for a longer PFS in men compared to women (log-rank p=0.054), HR for PFS in females versus males was 1.81 (95% CI 0.97-3.37, p=0.062). Disease control rate (DCR) was achieved in 55.7% and 45.7% of men and women, respectively, while disease progression was registered in 44.3% of males and 54.3% of females (p=0.386). Conclusion: Gender is a variable that should be taken into account in the choice of immunotherapy. Future prospective randomized trials testing tailored sex-based immunotherapy strategies are required to validate our findings before integrating into clinical practice.

Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer / Antonuzzo, Lorenzo; Caliman, Enrico; Petrella, Maria Cristina; Rossi, Virginia; Mazzoni, Francesca; Grosso, Anna Maria; Fancelli, Sara; Paglialunga, Luca; Comin, Camilla; Roviello, Giandomenico; Pillozzi, Serena. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - ELETTRONICO. - 22:(2022), pp. 0-0. [10.2174/1568009622666220831142452]

Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer

Antonuzzo, Lorenzo;Caliman, Enrico;Petrella, Maria Cristina;Rossi, Virginia;Grosso, Anna Maria;Fancelli, Sara;Comin, Camilla;Roviello, Giandomenico;Pillozzi, Serena
2022

Abstract

Background: Emerging evidence identified sex as a variable regulating immune system functions and modulating response to immunotherapy in cancer patients. Objective: This retrospective study analysed sex-related differences in immunotherapy outcomes in a real-world population of non-small cell lung cancer (NSCLC) patients treated with immune check point inhibitors (ICIs). Methods: We retrospectively investigated clinical data of 99 patients with advanced NSCLC and treated with single-agent nivolumab and pembrolizumab at Medical Oncology Unit, Careggi Universi ty Hospital, Florence (Italy), between April 2014 to August 2019. Main clinical characteristics and clinical outcomes were analysed. Results: Our study showed that the efficacy of ICI treatment differed according to gender. A trend for better median progression-free survival (mPFS) was reported in males (mPFS 5.0 months, 95% Con fidence Interval [CI] 4.0-11.0) than females (mPFS 4.5 months, 95% CI 2.0-9.0) (p=0.133), while no significant difference for overall survival (OS) between the two sex groups was observed (p=0.622). In the nivolumab cohort, we showed a statistically significant difference for a longer PFS in men compared to women (log-rank p=0.054), HR for PFS in females versus males was 1.81 (95% CI 0.97-3.37, p=0.062). Disease control rate (DCR) was achieved in 55.7% and 45.7% of men and women, respectively, while disease progression was registered in 44.3% of males and 54.3% of females (p=0.386). Conclusion: Gender is a variable that should be taken into account in the choice of immunotherapy. Future prospective randomized trials testing tailored sex-based immunotherapy strategies are required to validate our findings before integrating into clinical practice.
22
0
0
Antonuzzo, Lorenzo; Caliman, Enrico; Petrella, Maria Cristina; Rossi, Virginia; Mazzoni, Francesca; Grosso, Anna Maria; Fancelli, Sara; Paglialunga, Luca; Comin, Camilla; Roviello, Giandomenico; Pillozzi, Serena
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1286808
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact